` BCLI (Brainstorm Cell Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

BCLI
vs
S&P 500

Over the past 12 months, BCLI has underperformed S&P 500, delivering a return of -79% compared to the S&P 500's 9% growth.

Stocks Performance
BCLI vs S&P 500

Loading
BCLI
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
BCLI vs S&P 500

Loading
BCLI
S&P 500
Difference
www.alphaspread.com

Performance By Year
BCLI vs S&P 500

Loading
BCLI
S&P 500
Add Stock

Competitors Performance
Brainstorm Cell Therapeutics Inc vs Peers

S&P 500
BCLI
ABBV
AMGN
GILD
VRTX
Add Stock

Brainstorm Cell Therapeutics Inc
Glance View

Market Cap
9.6m USD
Industry
Biotechnology

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2003-05-28. The firm is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its phase III ALS and phase II PMS clinical trials. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd. holds the rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd., and two others.

BCLI Intrinsic Value
0.06 USD
Overvaluation 95%
Intrinsic Value
Price
Back to Top